Axiomer RNA editing shows strong phase 1 proof-of-concept for biliary atresia; key 2026–27 catalysts ahead. Click to read ...

RAP-219 Phase 3 catalyst, cash runway to 2029, long half-life pros/cons, valuation. Click here to read my analysis.

A research team led by Yang Lu from the Department of Mechanical Engineering at the Faculty of Engineering, The University of ...

WALTHAM, Mass. and HANGZHOU, China, Aug. 13, 2026 (GLOBE NEWSWIRE) -- . (“Photys”), a proximity-based therapeutics company, and Polymed Biopharmaceuticals, Inc. (“Polymed”), a global biotech company ...

Arcturus Therapeutics (NASDAQ:ARCT) is positioning its mRNA platform around two rare-disease programs targeting cystic ...

When different materials transition from one phase to another, such as water coming to a boil or a magnet losing its ability ...

Wnt pathway modulation, sustained-release TKI delivery, and topical steroid dosing are advancing through phase 3 trials in DME, testing approaches distinct from standard anti-VEGF injections.

The European Medicines Agency (EMA) is holding a consultation about a draft framework intended to cut the time it takes to ...

Metabones is bringing its TruePDAF Technology to Fujifilm cameras, and they have new products that completely replace the ...

Argenx stock is trading near $1,050 on the Nasdaq as of late August 2026, with recent trial success for VYVGART Hytrulo and ...

August 21, 2026 - PRESSADVANTAGE - GULLCO International, a manufacturer of welding and cutting automation equipment, ...

The financing will advance EPI-321, Epicrispr's lead clinical candidate currently in first-in-human studies for facioscapulohumeral muscular dystrophy (FSHD), accelerate its pipeline of programmable ...